BMY
Bristol-Myers Squibb Company · Healthcare
Insiders sold $2.3M of Bristol-Myers Squibb Company in the last 12 months and bought none
BMY over the last year
BMY after insider buys
3 months after each buy, from the first price a copier could get.
5 buys since 2017 with 3 months of prices.
Congress
Members reported 63 trades in BMY since 2023.
Every filing
94 insider filings since 2016, newest first
Cristian Massacesi · EVP,Chief Med Offr,Head of Dev
Phil M Holzer · SVP and Controller
David Elkins V · EVP and CFO
Samit Hirawat · EVP,Chief Med.Offr.,Drug Dev.
Christopher S. Boerner · CEO
Samit Hirawat · EVP,Chief Med.Offr.,Drug Dev.
Samit Hirawat · EVP,Chief Med.Offr.,Drug Dev.
Phil M Holzer · SVP, Controller
Christopher S. Boerner · CEO
Ann Powell · EVP, Chief HR
Robert M Plenge · EVP and Chief Research Officer
Rupert Vessey · EVP, Pres, Research
Giovanni Caforio · Board Chair, CEO
Ann Powell · EVP, Chief HR
Ann Powell · EVP, Chief HR
Rupert Vessey · EVP, Research, Early Dev.
Giovanni Caforio · Board Chair, CEO
Giovanni Caforio · Board Chair, CEO
David Elkins V · EVP and CFO
Ann Powell · EVP, Chief HR
Giovanni Caforio · Board Chair, CEO
Sandra Leung · EVP and General Counsel
Giovanni Caforio · Board Chair, CEO
Rupert Vessey · EVP, Research, Early Dev.
Karen Murphy Santiago · SVP, Controller
Christopher S. Boerner · EVP and Chief Commercial Officer
Giovanni Caforio · Board Chair, CEO
Rupert Vessey · EVP, Research, Early Dev.
Autenried Paul Von · EVP and CIO
Giovanni Caforio · Board Chair, CEO
David Elkins V · EVP and CFO
Giovanni Caforio · Chair and CEO
Ann Powell · EVP, Chief HR
Adam Dubow · SVP,ChiefCompliance, EthicsOff
Sandra Leung · EVP and General Counsel
Rupert Vessey · EVP, Research, Early Dev.
Autenried Paul Von · EVP and CIO
Joseph Eid · SVP,Head Glob. Medical Affairs
Louis S Schmukler · EVP,Pres,Glob.Prod., Supply
Adam Dubow · SVP,ChiefCompliance, EthicsOff
Rupert Vessey · EVP, Research, Early Dev.
Giovanni Caforio · Chair and CEO
Adam Dubow · SVP,ChiefCompliance, EthicsOff
Rupert Vessey · EVP, Research, Early Dev.
Autenried Paul Von · EVP and CIO
Rupert Vessey · EVP, Research, Early Dev.
Giovanni Caforio · Chair and CEO
Joseph Eid · SVP,Head Glob. Medical Affairs
Sandra Leung · EVP and General Counsel
Adam Dubow · SVP,ChiefCompliance, EthicsOff
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.